Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The potential anti-depressant and neuroprotective actions broaden their therapeutic scope
Furthermore, a prespecified subgroup analysis of HF individuals from the SELECT trial evaluating the effects of semaglutide on cardiovascular outcomes in people with overweight or obesity, which included 2,273 HFpEF and 1,347 HFrEF patients, showed that the therapy was associated with a reduction in the HF composite outcome (cardiovascular death or HF hospitalisation/emergency visit) across LVEF, suggesting that GLP-1 RAs may improve outcomes at least in obese HF patients regardless of diabetes status
How bizarre is that
Notably, unlike older diabetes medications, GLP-1 agonists carry minimal risk of hypoglycemia because their insulin stimulation is glucose-dependent ( [2] )
Heliyon 8 (11), e11411
US$ 25.43
US$ 25.38
US$ 25.35
US$ 21.17
US$ 23.55
US$ 27.05
US$ 22.60
US$ 20.80
US$ 23.25
